{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:28:54Z","timestamp":1792542534728,"version":"4.5.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002649","name":"Yeungnam University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002649","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Pharm. Investig."],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40005-022-00607-6","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T11:05:39Z","timestamp":1671447939000},"page":"19-33","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":234,"title":["Nanomedicine-based commercial formulations: current developments and future prospects"],"prefix":"10.1007","volume":"53","author":[{"given":"Raj Kumar","family":"Thapa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Oh","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"issue":"12","key":"607_CR1","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","volume":"14","author":"A Akinc","year":"2019","unstructured":"Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, Ansell S, Xinyao D, Hope MJ, Madden TD, Mui BL, Semple SC, Tam YK, Ciufolini M, Witzigmann D, Kulkarni JA, van der Meel R, Cullis PR (2019) The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol 14(12):1084\u20131087. https:\/\/doi.org\/10.1038\/s41565-019-0591-y","journal-title":"Nat Nanotechnol"},{"key":"607_CR2","doi-asserted-by":"publisher","first-page":"3041969","DOI":"10.1155\/2021\/3041969","volume":"2021","author":"LW Allahou","year":"2021","unstructured":"Allahou LW, Madani SY, Seifalian A (2021) Investigating the application of liposomes as drug delivery systems for the diagnosis and treatment of cancer. Int J Biomater 2021:3041969. https:\/\/doi.org\/10.1155\/2021\/3041969","journal-title":"Int J Biomater"},{"issue":"11","key":"607_CR3","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3390\/ph14111173","volume":"14","author":"MA Attia","year":"2021","unstructured":"Attia MA, Essa EA, Elebyary TT, Faheem AM, Elkordy AA (2021) Brief on recent application of liposomal vaccines for lower respiratory tract viral infections: from influenza to COVID-19 vaccines. Pharmaceuticals (Basel) 14(11):1173. https:\/\/doi.org\/10.3390\/ph14111173","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"607_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y (2012) Doxil\u00ae\u2014the first FDA-approved nano-drug: lessons learned. J Control Release 160(2):117\u2013134. https:\/\/doi.org\/10.1016\/j.jconrel.2012.03.020","journal-title":"J Control Release"},{"key":"607_CR5","doi-asserted-by":"publisher","first-page":"954","DOI":"10.12659\/msm.884024","volume":"19","author":"P Bartnicki","year":"2013","unstructured":"Bartnicki P, Fija\u0142kowski P, Majczyk M, B\u0142aszczyk J, Banach M, Rysz J (2013) Effect of methoxy polyethylene glycol-epoetin beta on oxidative stress in predialysis patients with chronic kidney disease. Med Sci Monit 19:954\u20139. https:\/\/doi.org\/10.12659\/msm.884024","journal-title":"Med Sci Monit"},{"key":"607_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25010112","author":"S Bayda","year":"2019","unstructured":"Bayda S, Adeel M, Tuccinardi T, Cordani M, Rizzolio F (2019) The history of nanoscience and nanotechnology: from chemical-physical applications to nanomedicine. Molecules. https:\/\/doi.org\/10.3390\/molecules25010112","journal-title":"Molecules"},{"issue":"9","key":"607_CR7","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1093\/ndt\/gfv096","volume":"30","author":"S Bhandari","year":"2015","unstructured":"Bhandari S, Kalra PA, Kothari J, Amb\u00fchl PM, Christensen JH, Essaian AM, Thomsen LL, Macdougall IC, Coyne DW (2015) A randomized, open-label trial of iron isomaltoside 1000 (Monofer\u00ae) compared with iron sucrose (Venofer\u00ae) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant 30(9):1577\u20131589. https:\/\/doi.org\/10.1093\/ndt\/gfv096","journal-title":"Nephrol Dial Transplant"},{"key":"607_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13020198","author":"S Bochicchio","year":"2021","unstructured":"Bochicchio S, Lamberti G, Barba AA (2021) Polymer-lipid pharmaceutical nanocarriers: innovations by new formulations and production technologies. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics13020198","journal-title":"Pharmaceutics"},{"issue":"8","key":"607_CR9","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/s1470-2045(19)30326-2","volume":"20","author":"S Bonvalot","year":"2019","unstructured":"Bonvalot S, Rutkowski PL, Thariat J, Carr\u00e8re S, Ducassou A, Sunyach MP, Agoston P, Hong A, Mervoyer A, Rastrelli M, Moreno V, Li RK, Tiangco B, Herraez AC, Gronchi A, Mangel L, Sy-Ortin T, Hohenberger P, de Ba\u00e8re T, Le Cesne A, Helfre S, Saada-Bouzid E, Borkowska A, Anghel R, Co A, Gebhart M, Kantor G, Montero A, Loong HH, Verg\u00e9s R, Lapeire L, Dema S, Kacso G, Austen L, Moureau-Zabotto L, Servois V, Wardelmann E, Terrier P, Lazar AJ, Le Jvmg Bov\u00e9e C (2019) NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act. In.Sarc): a multicentre, phase 2\u20133, randomised, controlled trial. Lancet Oncol 20(8):1148\u20131159. https:\/\/doi.org\/10.1016\/s1470-2045(19)30326-2","journal-title":"Lancet Oncol"},{"key":"607_CR10","first-page":"349","volume":"3","author":"C Booth","year":"2009","unstructured":"Booth C, Gaspar HB (2009) Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID). Biologics 3:349\u2013358","journal-title":"Biologics"},{"issue":"10","key":"607_CR11","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1007\/s12325-019-01058-6","volume":"36","author":"O Borg\u00e5","year":"2019","unstructured":"Borg\u00e5 O, Lilienberg E, Bjermo H, Hansson F, Heldring N, Dediu R (2019) Pharmacokinetics of total and unbound paclitaxel after administration of paclitaxel micellar or nab-paclitaxel: an open, randomized, cross-over, explorative study in breast cancer patients. Adv Ther 36(10):2825\u20132837. https:\/\/doi.org\/10.1007\/s12325-019-01058-6","journal-title":"Adv Ther"},{"issue":"7","key":"607_CR12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/j.1552-4604.1998.tb04464.x","volume":"38","author":"GW Boswell","year":"1998","unstructured":"Boswell GW, Buell D, Bekersky I (1998) AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol 38(7):583\u2013592. https:\/\/doi.org\/10.1002\/j.1552-4604.1998.tb04464.x","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"607_CR13","first-page":"624","volume":"41","author":"NM Bressler","year":"2000","unstructured":"Bressler NM, Bressler SB (2000) Photodynamic therapy with verteporfin (Visudyne): impact on ophthalmology and visual sciences. Invest Ophthalmol Vis Sci 41(3):624\u2013628","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"607_CR14","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3892\/ol.2016.4740","volume":"12","author":"J Brucker","year":"2016","unstructured":"Brucker J, Mayer C, Gebauer G, Mallmann P, Belau AK, Schneeweiss A, Sohn C, Eichbaum M (2016) Non-pegylated liposomal doxorubicin for patients with recurrent ovarian cancer: a multicentric phase II trial. Oncol Lett 12(2):1211\u20131215. https:\/\/doi.org\/10.3892\/ol.2016.4740","journal-title":"Oncol Lett"},{"issue":"1","key":"607_CR15","doi-asserted-by":"publisher","first-page":"e1416","DOI":"10.1002\/wnan.1416","volume":"9","author":"JM Caster","year":"2017","unstructured":"Caster JM, Patel AN, Zhang T, Wang A (2017) Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. WIREs Nanomed Nanobiotechnol 9(1):e1416. https:\/\/doi.org\/10.1002\/wnan.1416","journal-title":"WIREs Nanomed Nanobiotechnol"},{"issue":"1","key":"607_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40824-019-0166-x","volume":"23","author":"D Chenthamara","year":"2019","unstructured":"Chenthamara D, Subramaniam S, Ramakrishnan SG, Krishnaswamy S, Essa MM, Lin F-H, Walid Qoronfleh M (2019) Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res 23(1):20. https:\/\/doi.org\/10.1186\/s40824-019-0166-x","journal-title":"Biomater Res"},{"issue":"1","key":"607_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40005-017-0370-4","volume":"48","author":"YH Choi","year":"2018","unstructured":"Choi YH, Han H-K (2018) Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. J Pharm Investig 48(1):43\u201360. https:\/\/doi.org\/10.1007\/s40005-017-0370-4","journal-title":"J Pharm Investig"},{"key":"607_CR18","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2147\/ott.s79089","volume":"8","author":"H Chou","year":"2015","unstructured":"Chou H, Lin H, Liu JM (2015) A tale of the two PEGylated liposomal doxorubicins. Onco Targets Ther 8:1719\u20131720. https:\/\/doi.org\/10.2147\/ott.s79089","journal-title":"Onco Targets Ther"},{"issue":"1","key":"607_CR19","doi-asserted-by":"publisher","first-page":"e000942","DOI":"10.1136\/rmdopen-2019-000942","volume":"5","author":"JR Curtis","year":"2019","unstructured":"Curtis JR, Mariette X, Gaujoux-Viala C, Blauvelt A, Kvien TK, Sandborn WJ, Winthrop K, de Longueville M, Huybrechts I, Bykerk VP (2019) Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn\u2019s disease: a pooled analysis of 11,317 patients across clinical trials. RMD Open 5(1):e000942. https:\/\/doi.org\/10.1136\/rmdopen-2019-000942","journal-title":"RMD Open"},{"key":"607_CR20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.addr.2019.01.005","volume":"138","author":"SM Dadfar","year":"2019","unstructured":"Dadfar SM, Roemhild K, Drude NI, von Stillfried S, Kn\u00fcchel R, Kiessling F, Lammers T (2019) Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev 138:302\u2013325. https:\/\/doi.org\/10.1016\/j.addr.2019.01.005","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"607_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/ijn.s596","volume":"3","author":"WH De Jong","year":"2008","unstructured":"De Jong WH, Borm PJ (2008) Drug delivery and nanoparticles: applications and hazards. Int J Nanomed 3(2):133\u2013149. https:\/\/doi.org\/10.2147\/ijn.s596","journal-title":"Int J Nanomed"},{"issue":"2","key":"607_CR22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1208\/s12248-012-9339-4","volume":"14","author":"N Desai","year":"2012","unstructured":"Desai N (2012) Challenges in development of nanoparticle-based therapeutics. Aaps j 14(2):282\u2013295. https:\/\/doi.org\/10.1208\/s12248-012-9339-4","journal-title":"Aaps j"},{"issue":"3","key":"607_CR23","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s13346-021-01024-2","volume":"12","author":"S \u0110or\u0111evi\u0107","year":"2022","unstructured":"\u0110or\u0111evi\u0107 S, Gonzalez MM, Conejos-S\u00e1nchez I, Carreira B, Pozzi S, Ac\u00farcio RC, Satchi-Fainaro R, Florindo HF, Vicent MJ (2022) Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res 12(3):500\u2013525. https:\/\/doi.org\/10.1007\/s13346-021-01024-2","journal-title":"Drug Deliv Transl Res"},{"key":"607_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S1369-7021(05)71032-4","volume":"8","author":"R Duncan","year":"2005","unstructured":"Duncan R (2005) Nanomedicine gets clinical. Mater Today 8:16\u201317. https:\/\/doi.org\/10.1016\/S1369-7021(05)71032-4","journal-title":"Mater Today"},{"issue":"3","key":"607_CR25","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1111\/hae.13403","volume":"24","author":"AL Dunn","year":"2018","unstructured":"Dunn AL, Ahuja SP, Mullins ES (2018) Real-world experience with use of antihemophilic factor (Recombinant), PEGylated for prophylaxis in severe haemophilia A. Haemophilia 24(3):e84\u2013e92. https:\/\/doi.org\/10.1111\/hae.13403","journal-title":"Haemophilia"},{"issue":"4","key":"607_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2217\/14796694.4.4.457","volume":"4","author":"M Duvic","year":"2008","unstructured":"Duvic M, Talpur R (2008) Optimizing denileukin diftitox (Ontak) therapy. Future Oncol 4(4):457\u2013469. https:\/\/doi.org\/10.2217\/14796694.4.4.457","journal-title":"Future Oncol"},{"issue":"Suppl 10","key":"607_CR27","doi-asserted-by":"publisher","first-page":"S318","DOI":"10.4103\/2152-7806.159380","volume":"6","author":"NE Epstein","year":"2015","unstructured":"Epstein NE (2015) Preliminary study showing safety\/efficacy of nanoss bioactive versus vitoss as bone graft expanders for lumbar noninstrumented fusions. Surg Neurol Int 6(Suppl 10):S318\u2013S322. https:\/\/doi.org\/10.4103\/2152-7806.159380","journal-title":"Surg Neurol Int"},{"issue":"1","key":"607_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/104345429501200110","volume":"12","author":"AR Ettinger","year":"1995","unstructured":"Ettinger AR (1995) Pegaspargase (Oncaspar). J Pediatr Oncol Nurs 12(1):46\u201348. https:\/\/doi.org\/10.1177\/104345429501200110","journal-title":"J Pediatr Oncol Nurs"},{"issue":"1","key":"607_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/hae.13671","volume":"25","author":"M Ezban","year":"2019","unstructured":"Ezban M, Hermit MB, Persson E (2019) FIXing postinfusion monitoring: assay experiences with N9-GP (nonacog beta pegol; Refixia(\u00ae); Rebinyn(\u00ae)). Haemophilia 25(1):154\u2013161. https:\/\/doi.org\/10.1111\/hae.13671","journal-title":"Haemophilia"},{"issue":"1","key":"607_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2217\/nnm-2018-0120","volume":"14","author":"F Farjadian","year":"2019","unstructured":"Farjadian F, Ghasemi A, Gohari O, Roointan A, Karimi M, Hamblin MR (2019) Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine (lond) 14(1):93\u2013126. https:\/\/doi.org\/10.2217\/nnm-2018-0120","journal-title":"Nanomedicine (lond)"},{"issue":"4","key":"607_CR31","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/j.1748-720X.2012.00703.x","volume":"40","author":"L Fatehi","year":"2012","unstructured":"Fatehi L, Wolf SM, McCullough J, Hall R, Lawrenz F, Kahn JP, Jones C, Campbell SA, Dresser RS, Erdman AG, Haynes CL, Hoerr RA, Hogle LF, Keane MA, Khushf G, King NM, Kokkoli E, Marchant G, Maynard AD, Philbert M, Ramachandran G, Siegel RA, Wickline S (2012) Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging field. J Law Med Ethics 40(4):716\u2013750. https:\/\/doi.org\/10.1111\/j.1748-720X.2012.00703.x","journal-title":"J Law Med Ethics"},{"key":"607_CR32","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","volume":"11","author":"DB Fogel","year":"2018","unstructured":"Fogel DB (2018) Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun 11:156\u2013164. https:\/\/doi.org\/10.1016\/j.conctc.2018.08.001","journal-title":"Contemp Clin Trials Commun"},{"issue":"3","key":"607_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2165\/11204910-000000000-00000","volume":"12","author":"JE Frampton","year":"2010","unstructured":"Frampton JE (2010) Mifamurtide. Pediatr Drugs 12(3):141\u2013153. https:\/\/doi.org\/10.2165\/11204910-000000000-00000","journal-title":"Pediatr Drugs"},{"issue":"14","key":"607_CR34","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40265-016-0627-7","volume":"76","author":"KP Garnock-Jones","year":"2016","unstructured":"Garnock-Jones KP (2016) Fosaprepitant dimeglumine: a review in the prevention of nausea and vomiting associated with chemotherapy. Drugs 76(14):1365\u20131372. https:\/\/doi.org\/10.1007\/s40265-016-0627-7","journal-title":"Drugs"},{"issue":"3","key":"607_CR35","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/pharmaceutics10030134","volume":"10","author":"MR Gigliobianco","year":"2018","unstructured":"Gigliobianco MR, Casadidio C, Censi R, Di Martino P (2018) Nanocrystals of poorly soluble drugs: drug bioavailability and physicochemical stability. Pharmaceutics 10(3):134. https:\/\/doi.org\/10.3390\/pharmaceutics10030134","journal-title":"Pharmaceutics"},{"issue":"11","key":"607_CR36","first-page":"3394","volume":"5","author":"MJ Glantz","year":"1999","unstructured":"Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF, Howell SB (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5(11):3394\u20133402","journal-title":"Clin Cancer Res"},{"issue":"10","key":"607_CR37","first-page":"684","volume":"39","author":"K Gohil","year":"2014","unstructured":"Gohil K (2014) Pharmaceutical approval update. P t 39(10):684\u2013694","journal-title":"P t"},{"key":"607_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.addr.2018.07.007","volume":"130","author":"SK Golombek","year":"2018","unstructured":"Golombek SK, May JN, Theek B, Appold L, Drude N, Kiessling F, Lammers T (2018) Tumor targeting via EPR: Strategies to enhance patient responses. Adv Drug Deliv Rev 130:17\u201338. https:\/\/doi.org\/10.1016\/j.addr.2018.07.007","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"607_CR39","doi-asserted-by":"publisher","first-page":"e1531","DOI":"10.1002\/wnan.1531","volume":"11","author":"B Halamoda-Kenzaoui","year":"2019","unstructured":"Halamoda-Kenzaoui B, Holzwarth U, Roebben G, Bogni A, Bremer-Hoffmann S (2019) Mapping of the available standards against the regulatory needs for nanomedicines. WIREs Nanomed Nanobiotechnol 11(1):e1531. https:\/\/doi.org\/10.1002\/wnan.1531","journal-title":"WIREs Nanomed Nanobiotechnol"},{"issue":"9","key":"607_CR40","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1007\/s13346-022-01165-y","volume":"12","author":"B Halamoda-Kenzaoui","year":"2022","unstructured":"Halamoda-Kenzaoui B, Geertsma R, Pouw J, Prina-Mello A, Carrer M, Roesslein M, Sips A, Weltring KM, Spring K, Bremer-Hoffmann S (2022) Future perspectives for advancing regulatory science of nanotechnology-enabled health products. Drug Deliv Transl Res 12(9):2145\u20132156. https:\/\/doi.org\/10.1007\/s13346-022-01165-y","journal-title":"Drug Deliv Transl Res"},{"issue":"4","key":"607_CR41","doi-asserted-by":"publisher","first-page":"930","DOI":"10.20517\/cdr.2020.68","volume":"3","author":"I Hassanin","year":"2020","unstructured":"Hassanin I, Elzoghby A (2020) Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance. Cancer Drug Resist 3(4):930\u2013946. https:\/\/doi.org\/10.20517\/cdr.2020.68","journal-title":"Cancer Drug Resist"},{"issue":"6","key":"607_CR42","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1208\/s12248-016-9961-7","volume":"18","author":"H Havel","year":"2016","unstructured":"Havel H, Finch G, Strode P, Wolfgang M, Zale S, Bobe I, Youssoufian H, Peterson M, Liu M (2016) Nanomedicines: from bench to bedside and beyond. Aaps j 18(6):1373\u20131378. https:\/\/doi.org\/10.1208\/s12248-016-9961-7","journal-title":"Aaps j"},{"issue":"9","key":"607_CR43","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1021\/acs.accounts.9b00228","volume":"52","author":"H He","year":"2019","unstructured":"He H, Liu L, Morin EE, Liu M, Schwendeman A (2019) Survey of clinical translation of cancer nanomedicines\u2014lessons learned from successes and failures. Acc Chem Res 52(9):2445\u20132461. https:\/\/doi.org\/10.1021\/acs.accounts.9b00228","journal-title":"Acc Chem Res"},{"issue":"12","key":"607_CR44","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/ajhp\/zxab048","volume":"78","author":"JB Hertig","year":"2021","unstructured":"Hertig JB, Shah VP, Fl\u00fchmann B, M\u00fchlebach S, Stemer G, Surugue J, Moss R, Di Francesco T (2021) Tackling the challenges of nanomedicines: are we ready? Am J Health Syst Pharm 78(12):1047\u20131056. https:\/\/doi.org\/10.1093\/ajhp\/zxab048","journal-title":"Am J Health Syst Pharm"},{"issue":"33","key":"607_CR45","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1016\/j.vaccine.2009.05.029","volume":"27","author":"C Herzog","year":"2009","unstructured":"Herzog C, Hartmann K, K\u00fcnzi V, K\u00fcrsteiner O, Mischler R, Lazar H, Gl\u00fcck R (2009) Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine 27(33):4381\u20134387. https:\/\/doi.org\/10.1016\/j.vaccine.2009.05.029","journal-title":"Vaccine"},{"issue":"7","key":"607_CR46","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3390\/pharmaceutics12070604","volume":"12","author":"S Hong","year":"2020","unstructured":"Hong S, Choi DW, Kim HN, Park CG, Lee W, Park HH (2020) Protein-based nanoparticles as drug delivery systems. Pharmaceutics 12(7):604. https:\/\/doi.org\/10.3390\/pharmaceutics12070604","journal-title":"Pharmaceutics"},{"issue":"1","key":"607_CR47","first-page":"41","volume":"27","author":"SA Hood","year":"2000","unstructured":"Hood SA, O\u2019Brien M, Higgins R (2000) The safety of intravenous iron dextran (Dexferrum) during hemodialysis in patients with end stage renal disease. Nephrol Nurs J 27(1):41\u201342","journal-title":"Nephrol Nurs J"},{"key":"607_CR48","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3389\/fphar.2018.00790","volume":"9","author":"S Hua","year":"2018","unstructured":"Hua S, de Matos MBC, Metselaar JM, Storm G (2018) Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Front Pharmacol 9:790. https:\/\/doi.org\/10.3389\/fphar.2018.00790","journal-title":"Front Pharmacol"},{"issue":"4","key":"607_CR49","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1586\/14787210.3.4.495","volume":"3","author":"CK Hui","year":"2005","unstructured":"Hui CK, Lau GK (2005) Peginterferon-alpha2a (40 kDa) (Pegasys) for hepatitis B. Expert Rev Anti Infect Ther 3(4):495\u2013504. https:\/\/doi.org\/10.1586\/14787210.3.4.495","journal-title":"Expert Rev Anti Infect Ther"},{"key":"607_CR50","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.csbj.2016.06.007","volume":"14","author":"R Jacquemart","year":"2016","unstructured":"Jacquemart R, Vandersluis M, Zhao M, Sukhija K, Sidhu N, Stout J (2016) A single-use strategy to enable manufacturing of affordable biologics. Comput Struct Biotechnol J 14:309\u2013318. https:\/\/doi.org\/10.1016\/j.csbj.2016.06.007","journal-title":"Comput Struct Biotechnol J"},{"issue":"2","key":"607_CR51","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000112961","volume":"17","author":"KK Jain","year":"2008","unstructured":"Jain KK (2008) Nanomedicine: application of nanobiotechnology in medical practice. Med Princ Pract 17(2):89\u2013101. https:\/\/doi.org\/10.1159\/000112961","journal-title":"Med Princ Pract"},{"key":"607_CR52","first-page":"6","volume":"236","author":"JS James","year":"1995","unstructured":"James JS (1995) DOXIL approved for KS. AIDS Treat News 236:6","journal-title":"AIDS Treat News"},{"issue":"4","key":"607_CR53","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2174\/2211738507666190405182524","volume":"7","author":"K Joshi","year":"2019","unstructured":"Joshi K, Chandra A, Jain K, Talegaonkar S (2019) Nanocrystalization: an emerging technology to enhance the bioavailability of poorly soluble drugs. Pharm Nanotechnol 7(4):259\u2013278. https:\/\/doi.org\/10.2174\/2211738507666190405182524","journal-title":"Pharm Nanotechnol"},{"issue":"1","key":"607_CR54","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/1074248410395020","volume":"17","author":"N Kaddar","year":"2012","unstructured":"Kaddar N, Vigneault P, Pilote S, Patoine D, Simard C, Drolet B (2012) Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking IKr. J Cardiovasc Pharmacol Ther 17(1):102\u2013109. https:\/\/doi.org\/10.1177\/1074248410395020","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"4","key":"607_CR55","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1021\/acs.chemrev.5b00346","volume":"116","author":"N Kamaly","year":"2016","unstructured":"Kamaly N, Yameen B, Wu J, Farokhzad OC (2016) Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev 116(4):2602\u20132663. https:\/\/doi.org\/10.1021\/acs.chemrev.5b00346","journal-title":"Chem Rev"},{"key":"607_CR56","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jconrel.2014.06.005","volume":"193","author":"IP Kaur","year":"2014","unstructured":"Kaur IP, Kakkar V, Deol PK, Yadav M, Singh M, Sharma I (2014) Issues and concerns in nanotech product development and its commercialization. J Control Release 193:51\u201362. https:\/\/doi.org\/10.1016\/j.jconrel.2014.06.005","journal-title":"J Control Release"},{"key":"607_CR57","doi-asserted-by":"publisher","first-page":"676025","DOI":"10.3389\/fmedt.2021.676025","volume":"3","author":"P Kiran","year":"2021","unstructured":"Kiran P, Khan A, Neekhra S, Pallod S, Srivastava R (2021) Nanohybrids as protein-polymer conjugate multimodal therapeutics. Front Med Technol 3:676025. https:\/\/doi.org\/10.3389\/fmedt.2021.676025","journal-title":"Front Med Technol"},{"key":"607_CR58","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejpb.2017.03.006","volume":"117","author":"F Lallemand","year":"2017","unstructured":"Lallemand F, Schmitt M, Bourges J-L, Gurny R, Benita S, Garrigue J-S (2017) Cyclosporine A delivery to the eye: a comprehensive review of academic and industrial efforts. Eur J Pharm Biopharm 117:14\u201328. https:\/\/doi.org\/10.1016\/j.ejpb.2017.03.006","journal-title":"Eur J Pharm Biopharm"},{"key":"607_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1450","author":"Y Lee","year":"2017","unstructured":"Lee Y, Thompson DH (2017) Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. https:\/\/doi.org\/10.1002\/wnan.1450","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"4","key":"607_CR60","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.biotechadv.2013.11.006","volume":"32","author":"PC Lin","year":"2014","unstructured":"Lin PC, Lin S, Wang PC, Sridhar R (2014) Techniques for physicochemical characterization of nanomaterials. Biotechnol Adv 32(4):711\u2013726. https:\/\/doi.org\/10.1016\/j.biotechadv.2013.11.006","journal-title":"Biotechnol Adv"},{"key":"607_CR61","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.addr.2020.06.020","volume":"156","author":"DC Luther","year":"2020","unstructured":"Luther DC, Huang R, Jeon T, Zhang X, Lee YW, Nagaraj H, Rotello VM (2020) Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles. Adv Drug Deliv Rev 156:188\u2013213. https:\/\/doi.org\/10.1016\/j.addr.2020.06.020","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"607_CR62","first-page":"29","volume":"2","author":"J Mack","year":"2005","unstructured":"Mack J (2005) Nanotechnology: what\u2019s in it for biotech? Biotechnol Healthc 2(6):29\u201336","journal-title":"Biotechnol Healthc"},{"key":"607_CR63","doi-asserted-by":"publisher","first-page":"e12392","DOI":"10.7717\/peerj.12392","volume":"9","author":"R Malviya","year":"2021","unstructured":"Malviya R, Fuloria S, Verma S, Subramaniyan V, Sathasivam KV, Kumarasamy V, Hari Kumar D, Vellasamy S, Meenakshi DU, Yadav S, Sharma A, Fuloria NK (2021) Commercial utilities and future perspective of nanomedicines. PeerJ 9:e12392. https:\/\/doi.org\/10.7717\/peerj.12392","journal-title":"PeerJ"},{"issue":"1","key":"607_CR64","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s43094-022-00400-0","volume":"8","author":"ZM Mazayen","year":"2022","unstructured":"Mazayen ZM, Ghoneim AM, Elbatanony RS, Basalious EB, Bendas ER (2022) Pharmaceutical nanotechnology: from the bench to the market. Future J Pharm Sci 8(1):12. https:\/\/doi.org\/10.1186\/s43094-022-00400-0","journal-title":"Future J Pharm Sci"},{"issue":"7","key":"607_CR65","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1111\/cas.15377","volume":"113","author":"G Milano","year":"2022","unstructured":"Milano G, Innocenti F, Minami H (2022) Liposomal irinotecan (Onivyde): exemplifying the benefits of nanotherapeutic drugs. Cancer Sci 113(7):2224\u20132231. https:\/\/doi.org\/10.1111\/cas.15377","journal-title":"Cancer Sci"},{"issue":"2","key":"607_CR66","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R (2021) Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discovery 20(2):101\u2013124. https:\/\/doi.org\/10.1038\/s41573-020-0090-8","journal-title":"Nat Rev Drug Discovery"},{"issue":"12","key":"607_CR67","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2165\/11201140-000000000-00000","volume":"23","author":"MD Moen","year":"2009","unstructured":"Moen MD, Keam SJ (2009) Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder. CNS Drugs 23(12):1057\u20131083. https:\/\/doi.org\/10.2165\/11201140-000000000-00000","journal-title":"CNS Drugs"},{"key":"607_CR68","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.addr.2018.06.024","volume":"131","author":"S M\u00fchlebach","year":"2018","unstructured":"M\u00fchlebach S (2018) Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach? Adv Drug Delivery Rev 131:122\u2013131. https:\/\/doi.org\/10.1016\/j.addr.2018.06.024","journal-title":"Adv Drug Delivery Rev"},{"issue":"6","key":"607_CR69","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1254\/fpj.137.245","volume":"137","author":"K Nagino","year":"2011","unstructured":"Nagino K, Koh T, Harada Y (2011) Pharmacological properties of paliperidone ER (INVEGA(\u00ae)) and results of its clinical studies. Nihon Yakurigaku Zasshi 137(6):245\u2013254. https:\/\/doi.org\/10.1254\/fpj.137.245","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"607_CR70","doi-asserted-by":"publisher","first-page":"705886","DOI":"10.3389\/fbioe.2021.705886","volume":"9","author":"P Nakhaei","year":"2021","unstructured":"Nakhaei P, Margiana R, Bokov DO, Abdelbasset WK, Jadidi Kouhbanani MA, Varma RS, Marofi F, Jarahian M, Beheshtkhoo N (2021) Liposomes: structure, biomedical applications, and stability parameters with emphasis on cholesterol. Front Bioeng Biotechnol 9:705886. https:\/\/doi.org\/10.3389\/fbioe.2021.705886","journal-title":"Front Bioeng Biotechnol"},{"issue":"12","key":"607_CR71","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1007\/s11095-010-0233-4","volume":"27","author":"C Oerlemans","year":"2010","unstructured":"Oerlemans C, Bult W, Bos M, Storm G, Nijsen JF, Hennink WE (2010) Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res 27(12):2569\u20132589. https:\/\/doi.org\/10.1007\/s11095-010-0233-4","journal-title":"Pharm Res"},{"key":"607_CR72","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.2147\/ijn.s38378","volume":"9","author":"S Onoue","year":"2014","unstructured":"Onoue S, Yamada S, Chan HK (2014) Nanodrugs: pharmacokinetics and safety. Int J Nanomed 9:1025\u20131037. https:\/\/doi.org\/10.2147\/ijn.s38378","journal-title":"Int J Nanomed"},{"key":"607_CR73","volume-title":"StatPearls","author":"IS Padda","year":"2022","unstructured":"Padda IS, Bhatt R, Parmar M (2022) Pegloticase. StatPearls. StatPearls Publishing, Treasure Island"},{"issue":"4","key":"607_CR75","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s40265-019-01083-3","volume":"79","author":"J Paik","year":"2019","unstructured":"Paik J, Duggan ST, Keam SJ (2019) Triamcinolone acetonide extended-release: a review in osteoarthritis pain of the knee. Drugs 79(4):455\u2013462. https:\/\/doi.org\/10.1007\/s40265-019-01083-3","journal-title":"Drugs"},{"issue":"6","key":"607_CR76","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1208\/s12249-014-0177-9","volume":"15","author":"R Paliwal","year":"2014","unstructured":"Paliwal R, Babu RJ, Palakurthi S (2014) Nanomedicine scale-up technologies: feasibilities and challenges. AAPS PharmSciTech 15(6):1527\u20131534. https:\/\/doi.org\/10.1208\/s12249-014-0177-9","journal-title":"AAPS PharmSciTech"},{"issue":"10","key":"607_CR77","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S0169-409X(03)00111-X","volume":"55","author":"C Parkinson","year":"2003","unstructured":"Parkinson C, Scarlett JA, Trainer PJ (2003) Pegvisomant in the treatment of acromegaly. Adv Drug Delivery Rev 55(10):1303\u20131314. https:\/\/doi.org\/10.1016\/S0169-409X(03)00111-X","journal-title":"Adv Drug Delivery Rev"},{"issue":"5","key":"607_CR78","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jopan.2005.07.004","volume":"20","author":"C Pasero","year":"2005","unstructured":"Pasero C, McCaffery M (2005) Extended-release epidural morphine (DepoDur\u2122). J PeriAnesthesia Nurs 20(5):345\u2013350. https:\/\/doi.org\/10.1016\/j.jopan.2005.07.004","journal-title":"J PeriAnesthesia Nurs"},{"issue":"1","key":"607_CR79","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","volume":"16","author":"JK Patra","year":"2018","unstructured":"Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin HS (2018) Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology 16(1):71. https:\/\/doi.org\/10.1186\/s12951-018-0392-8","journal-title":"J Nanobiotechnology"},{"issue":"3","key":"607_CR80","first-page":"31","volume":"19","author":"E Prommer","year":"2005","unstructured":"Prommer E (2005) Aprepitant (EMEND): the role of substance P in nausea and vomiting. J Pain Palliat Care Pharmacother 19(3):31\u201339","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"6","key":"607_CR81","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1615\/critrevtherdrugcarriersyst.v26.i6.10","volume":"26","author":"A Puri","year":"2009","unstructured":"Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, Blumenthal R (2009) Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst 26(6):523\u2013580. https:\/\/doi.org\/10.1615\/critrevtherdrugcarriersyst.v26.i6.10","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"3","key":"607_CR82","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1055\/s-2004-823779","volume":"21","author":"R Ramanathan","year":"2004","unstructured":"Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K (2004) A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 21(3):109\u2013119. https:\/\/doi.org\/10.1055\/s-2004-823779","journal-title":"Am J Perinatol"},{"issue":"2","key":"607_CR83","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/s1040-8428(00)00107-4","volume":"37","author":"MR Ranson","year":"2001","unstructured":"Ranson MR, Cheeseman S, White S, Margison J (2001) Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. Crit Rev Oncol Hematol 37(2):115\u2013120. https:\/\/doi.org\/10.1016\/s1040-8428(00)00107-4","journal-title":"Crit Rev Oncol Hematol"},{"key":"607_CR84","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.critrevonc.2016.07.008","volume":"105","author":"D Rizzieri","year":"2016","unstructured":"Rizzieri D (2016) Zevalin(\u00ae) (ibritumomab tiuxetan): after more than a decade of treatment experience, what have we learned? Crit Rev Oncol Hematol 105:5\u201317. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.07.008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"607_CR85","first-page":"35","volume":"25","author":"DM Rust","year":"1998","unstructured":"Rust DM, Jameson G (1998) The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice. Oncol Nurs Forum 25(1):35\u201348","journal-title":"Oncol Nurs Forum"},{"key":"607_CR86","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2147\/ppa.s104259","volume":"10","author":"JA Sacrist\u00e1n","year":"2016","unstructured":"Sacrist\u00e1n JA, Aguar\u00f3n A, Avenda\u00f1o-Sol\u00e1 C, Garrido P, Carri\u00f3n J, Guti\u00e9rrez A, Kroes R, Flores A (2016) Patient involvement in clinical research: why, when, and how. Patient Prefer Adherence 10:631\u2013640. https:\/\/doi.org\/10.2147\/ppa.s104259","journal-title":"Patient Prefer Adherence"},{"key":"607_CR87","first-page":"3","volume":"246","author":"K Sarcoma","year":"1996","unstructured":"Sarcoma K (1996) Kaposi\u2019s sarcoma: DaunoXome approved. AIDS Treat News 246:3\u20134","journal-title":"AIDS Treat News"},{"issue":"5","key":"607_CR88","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1517\/14656566.2012.658774","volume":"13","author":"A Saurav","year":"2012","unstructured":"Saurav A, Kaushik M, Mohiuddin SM (2012) Fenofibric acid for hyperlipidemia. Expert Opin Pharmacother 13(5):717\u2013722. https:\/\/doi.org\/10.1517\/14656566.2012.658774","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"607_CR89","first-page":"1369","volume":"3","author":"MR Semenchuk","year":"2002","unstructured":"Semenchuk MR (2002) Avinza Elan. Curr Opin Investig Drugs 3(9):1369\u20131372","journal-title":"Curr Opin Investig Drugs"},{"key":"607_CR90","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fphar.2015.00286","volume":"6","author":"L Sercombe","year":"2015","unstructured":"Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S (2015) Advances and challenges of liposome assisted drug delivery. Front Pharmacol 6:286. https:\/\/doi.org\/10.3389\/fphar.2015.00286","journal-title":"Front Pharmacol"},{"issue":"7","key":"607_CR91","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1016\/j.apsb.2022.02.025","volume":"12","author":"X Shan","year":"2022","unstructured":"Shan X, Gong X, Li J, Wen J, Li Y, Zhang Z (2022) Current approaches of nanomedicines in the market and various stage of clinical translation. Acta Pharm Sin B 12(7):3028\u20133048. https:\/\/doi.org\/10.1016\/j.apsb.2022.02.025","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"607_CR92","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s40820-022-00922-5","volume":"14","author":"S Sharifi","year":"2022","unstructured":"Sharifi S, Mahmoud NN, Voke E, Landry MP, Mahmoudi M (2022) Importance of standardizing analytical characterization methodology for improved reliability of the nanomedicine literature. Nano-Micro Lett 14(1):172. https:\/\/doi.org\/10.1007\/s40820-022-00922-5","journal-title":"Nano-Micro Lett"},{"issue":"3","key":"607_CR93","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00280-012-2042-4","volume":"71","author":"JA Silverman","year":"2013","unstructured":"Silverman JA, Deitcher SR (2013) Marqibo\u00ae (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol 71(3):555\u2013564. https:\/\/doi.org\/10.1007\/s00280-012-2042-4","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"607_CR94","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/01.gme.0000174096.56652.4f","volume":"13","author":"JA Simon","year":"2006","unstructured":"Simon JA (2006) Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause 13(2):222\u2013231. https:\/\/doi.org\/10.1097\/01.gme.0000174096.56652.4f","journal-title":"Menopause"},{"issue":"1","key":"607_CR95","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41392-019-0068-3","volume":"4","author":"AP Singh","year":"2019","unstructured":"Singh AP, Biswas A, Shukla A, Maiti P (2019) Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal Transduct Target Ther 4(1):33. https:\/\/doi.org\/10.1038\/s41392-019-0068-3","journal-title":"Signal Transduct Target Ther"},{"key":"607_CR96","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3389\/fchem.2018.00360","volume":"6","author":"S Soares","year":"2018","unstructured":"Soares S, Sousa J, Pais A, Vitorino C (2018) Nanomedicine: principles, properties, and regulatory issues. Front Chem 6:360. https:\/\/doi.org\/10.3389\/fchem.2018.00360","journal-title":"Front Chem"},{"issue":"6","key":"607_CR97","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/22201173.2008.10872573","volume":"14","author":"N Terblanche","year":"2008","unstructured":"Terblanche N, Coetzee JF (2008) A comparison of induction of anaesthesia using two different propofol preparations. South Afr J Anaesth Analg 14(6):25\u201329. https:\/\/doi.org\/10.1080\/22201173.2008.10872573","journal-title":"South Afr J Anaesth Analg"},{"issue":"1","key":"607_CR98","first-page":"11","volume":"31","author":"KA Tobin","year":"2006","unstructured":"Tobin KA (2006) Macugen treatment for wet age-related macular degeneration. Insight 31(1):11\u201314","journal-title":"Insight"},{"issue":"7","key":"607_CR99","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1517\/14712598.2014.907784","volume":"14","author":"TC Tseng","year":"2014","unstructured":"Tseng TC, Kao JH, Chen DS (2014) Peginterferon \u03b1 in the treatment of chronic hepatitis B. Expert Opin Biol Ther 14(7):995\u20131006. https:\/\/doi.org\/10.1517\/14712598.2014.907784","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"607_CR100","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.critrevonc.2013.07.015","volume":"88","author":"A Tuca","year":"2013","unstructured":"Tuca A, Jimenez-Fonseca P, Gasc\u00f3n P (2013) Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol 88(3):625\u2013636. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.07.015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"607_CR101","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1177\/0956797617708234","volume":"28","author":"C Van den Driessche","year":"2017","unstructured":"Van den Driessche C, Bastian M, Peyre H, Stordeur C, Acquaviva \u00c9, Bahadori S, Delorme R, Sackur J (2017) Attentional lapses in attention-deficit\/hyperactivity disorder: blank rather than wandering thoughts. Psychol Sci 28(10):1375\u20131386. https:\/\/doi.org\/10.1177\/0956797617708234","journal-title":"Psychol Sci"},{"issue":"1","key":"607_CR102","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12951-022-01605-4","volume":"20","author":"S Waheed","year":"2022","unstructured":"Waheed S, Li Z, Zhang F, Chiarini A, Armato U, Jun W (2022) Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. J Nanobiotechnol 20(1):395. https:\/\/doi.org\/10.1186\/s12951-022-01605-4","journal-title":"J Nanobiotechnol"},{"issue":"6","key":"607_CR103","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1208\/s12248-015-9814-9","volume":"17","author":"H Wen","year":"2015","unstructured":"Wen H, Jung H, Li X (2015) Drug delivery approaches in addressing clinical pharmacology-related issues: opportunities and challenges. Aaps j 17(6):1327\u20131340. https:\/\/doi.org\/10.1208\/s12248-015-9814-9","journal-title":"Aaps j"},{"issue":"1","key":"607_CR104","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.nano.2016.08.016","volume":"13","author":"T Yadavalli","year":"2017","unstructured":"Yadavalli T, Shukla D (2017) Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections. Nanomedicine 13(1):219\u2013230. https:\/\/doi.org\/10.1016\/j.nano.2016.08.016","journal-title":"Nanomedicine"},{"issue":"9","key":"607_CR105","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.3390\/molecules25092193","volume":"25","author":"AA Yetisgin","year":"2020","unstructured":"Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O (2020) Therapeutic nanoparticles and their targeted delivery applications. Molecules 25(9):2193. https:\/\/doi.org\/10.3390\/molecules25092193","journal-title":"Molecules"},{"issue":"7","key":"607_CR106","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1021\/acs.molpharmaceut.9b01221","volume":"17","author":"H Yuan","year":"2020","unstructured":"Yuan H, Guo H, Luan X, He M, Li F, Burnett J, Truchan N, Sun D (2020) albumin nanoparticle of paclitaxel (Abraxane) decreases while taxol increases breast cancer stem cells in treatment of triple negative breast cancer. Mol Pharm 17(7):2275\u20132286. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b01221","journal-title":"Mol Pharm"},{"issue":"1","key":"607_CR107","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.addr.2012.10.003","volume":"65","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Chan HF, Leong KW (2013) Advanced materials and processing for drug delivery: the past and the future. Adv Drug Deliv Rev 65(1):104\u2013120. https:\/\/doi.org\/10.1016\/j.addr.2012.10.003","journal-title":"Adv Drug Deliv Rev"},{"key":"607_CR108","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jconrel.2016.06.012","volume":"240","author":"RX Zhang","year":"2016","unstructured":"Zhang RX, Wong HL, Xue HY, Eoh JY, Wu XY (2016) Nanomedicine of synergistic drug combinations for cancer therapy\u2014strategies and perspectives. J Control Release 240:489\u2013503. https:\/\/doi.org\/10.1016\/j.jconrel.2016.06.012","journal-title":"J Control Release"},{"issue":"1","key":"607_CR109","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cac2.12225","volume":"42","author":"J Zhang","year":"2022","unstructured":"Zhang J, Pan Y, Shi Q, Zhang G, Jiang L, Dong X, Gu K, Wang H, Zhang X, Yang N, Li Y, Xiong J, Yi T, Peng M, Song Y, Fan Y, Cui J, Chen G, Tan W, Zang A, Guo Q, Zhao G, Wang Z, He J, Yao W, Wu X, Chen K, Hu X, Hu C, Yue L, Jiang D, Wang G, Liu J, Yu G, Li J, Bai J, Xie W, Zhao W, Wu L, Zhou C (2022) Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: a multicenter, randomized, open-label, parallel controlled clinical study. Cancer Commun (lond) 42(1):3\u201316. https:\/\/doi.org\/10.1002\/cac2.12225","journal-title":"Cancer Commun (lond)"}],"container-title":["Journal of Pharmaceutical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40005-022-00607-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40005-022-00607-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40005-022-00607-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T14:35:10Z","timestamp":1744209310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40005-022-00607-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":108,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["607"],"URL":"https:\/\/doi.org\/10.1007\/s40005-022-00607-6","relation":{},"ISSN":["2093-5552","2093-6214"],"issn-type":[{"value":"2093-5552","type":"print"},{"value":"2093-6214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]},"assertion":[{"value":"21 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors (R.K. Thapa and J.O. Kim) declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human and animal subjects performed by the author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal rights"}}]}}